{"product_id":"tesamorelin-th9507","title":"Tesamorelin (TH9507) Peptide","description":"\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eTesamorelin | TH9507 | Stabilised Growth Hormone-Releasing Hormone Analogue | Research Peptide\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eAlso Known As:\u003c\/strong\u003e TH9507, Egrifta (pharmaceutical brand name) \u003cstrong\u003eSequence:\u003c\/strong\u003e Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu (44 residues, N-terminally modified) \u003cstrong\u003eModification:\u003c\/strong\u003e Trans-3-hexenoic acid moiety conjugated to N-terminal tyrosine residue \u003cstrong\u003eMolecular Formula:\u003c\/strong\u003e C₂₂₁H₃₆₆N₇₂O₆₇S \u003cstrong\u003eMolecular Weight:\u003c\/strong\u003e 5135.77 g\/mol \u003cstrong\u003ePurity:\u003c\/strong\u003e \u0026gt;99% (HPLC verified) \u003cstrong\u003eForm:\u003c\/strong\u003e Lyophilised powder \u003cstrong\u003eAvailable Sizes:\u003c\/strong\u003e 5mg | 10mg \u003cstrong\u003eStorage:\u003c\/strong\u003e 2–8°C (refrigerated); –20°C for long-term storage \u003cstrong\u003eCAS Number:\u003c\/strong\u003e 218949-48-5\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eWhat Is Tesamorelin?\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eTesamorelin (developmental code: TH9507; brand name Egrifta) is a synthetic 44-amino acid analogue of endogenous human growth hormone-releasing hormone (GHRH), developed by Theratechnologies Inc. and approved by the U.S. Food and Drug Administration (FDA) in 2010 — making it one of the very few research-grade peptides with full FDA approval and an extensive human clinical trial dataset behind it.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eEndogenous GHRH is a 44-amino acid hypothalamic peptide that binds to GHRH receptors on somatotroph cells in the anterior pituitary, stimulating the synthesis and pulsatile secretion of growth hormone (GH). While native GHRH is pharmacologically active, it is rapidly degraded in vivo by the serum enzyme dipeptidyl peptidase-4 (DPP-4) — which cleaves at the Tyr-Ala bond at the N-terminus — resulting in a biological half-life of only a few minutes and rendering it largely unsuitable as a sustained research tool.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eTesamorelin addresses this limitation through a precise structural modification: conjugation of a trans-3-hexenoic acid moiety to the N-terminal tyrosine residue. This hydrophobic modification sterically protects the DPP-4 cleavage site, producing a compound with significantly enhanced metabolic stability while retaining full agonist activity at the GHRH receptor. The result is a peptide that reproduces the physiological pulsatile pattern of GH secretion — preserving the natural hypothalamic-pituitary feedback architecture — rather than delivering continuous, supraphysiological GH exposure as exogenous rhGH administration does. This key distinction has major implications for research design and for the safety and hormonal specificity profile of tesamorelin relative to direct GH administration.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eOur tesamorelin is synthesised under strict quality-controlled manufacturing conditions, verified to a purity of greater than 99% by High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS), and supplied as a lyophilised (freeze-dried) powder for optimal stability.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eResearch Background \u0026amp; Clinical Data\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eTesamorelin carries one of the most extensive and rigorously validated clinical research profiles of any peptide available for laboratory study. It has been evaluated in large-scale, randomised, double-blind, placebo-controlled Phase III trials involving over 800 participants, with findings published in leading peer-reviewed journals. This level of clinical evidence is exceptional within the research peptide landscape and makes tesamorelin a uniquely robust reference compound for the GH\/IGF-1 axis.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eMechanism: GHRH Receptor Activation \u0026amp; Pulsatile GH Secretion\u003c\/strong\u003e Tesamorelin binds with high affinity to the growth hormone-releasing hormone receptor (GHRH-R) — a G-protein-coupled receptor expressed predominantly on somatotroph cells of the anterior pituitary. Receptor binding activates the adenylate cyclase–cAMP–PKA intracellular signalling cascade, promoting both acute GH release and longer-term GH gene transcription. Critically, this mechanism preserves the natural pulsatile pattern of GH secretion and maintains hypothalamic-pituitary IGF-1 feedback inhibition — meaning GH release remains physiologically regulated rather than driven to sustained supraphysiological levels. Downstream, elevated GH stimulates hepatic and peripheral production of IGF-1 and IGF binding protein-3 (IGFBP-3), which mediate the compound's anabolic, lipolytic, and tissue-remodelling effects at target tissues.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003ePulsatile GH Augmentation — Clinical Study in Healthy Males\u003c\/strong\u003e A landmark mechanistic study published in the Journal of Clinical Endocrinology \u0026amp; Metabolism examined the effects of tesamorelin at 2 mg daily for two weeks in 13 healthy males. Tesamorelin significantly increased mean overnight GH, average GH peak area, and basal GH secretion. IGF-1 increased by 181 ± 22 μg\/litre (P \u0026lt; 0.0001), while neither fasting glucose nor insulin-stimulated glucose uptake was significantly affected — an important finding demonstrating that tesamorelin's GH stimulation can substantially elevate IGF-1 without impairing peripheral insulin sensitivity, a key differentiator from direct exogenous rhGH administration.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003ePhase III Clinical Trials: HIV-Associated Lipodystrophy (LIPO-010 \u0026amp; CTR-1011)\u003c\/strong\u003e The pivotal Phase III evidence base for tesamorelin comprises two large, multicentre, randomised, double-blind, placebo-controlled trials — LIPO-010 (n=412) and CTR-1011 (n=404) — enrolling a combined total of 816 HIV-infected patients with excess visceral adiposity associated with antiretroviral therapy. Across both trials, tesamorelin demonstrated consistent reductions in visceral adipose tissue (VAT) of approximately 15–20%, accompanied by improvements in triglycerides, waist circumference, and patient-reported body image outcomes. These results were robust, reproducible across both trials, and formed the basis of the compound's FDA approval in 2010 as the first and only medication specifically indicated for reducing excess abdominal fat in HIV-infected patients with lipodystrophy. An important finding from these trials was that tesamorelin significantly reduced visceral adipose tissue without adversely affecting subcutaneous fat or inducing insulin resistance — a clinically meaningful distinction from direct GH therapy.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eNAFLD \u0026amp; Liver Fat Research — The Lancet HIV\u003c\/strong\u003e Beyond visceral fat reduction, tesamorelin has been studied in models of metabolic dysfunction-associated liver disease. Tesamorelin is also being evaluated as therapy for insulin resistance, obesity, and nonalcoholic fatty liver disease. In a substudy examining HIV-positive participants with NAFLD, tesamorelin produced clinically meaningful reductions in liver fat content and, in some analyses, attenuation of fibrosis progression markers — findings of significant interest to researchers working in hepatology and liver metabolic disease.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eCardiovascular Research\u003c\/strong\u003e In a study of tesamorelin (2 mg\/day subcutaneously) in 60 abdominally obese volunteers with reduced peak GH stimulation, 12 months of treatment significantly decreased carotid intima-media thickness (cIMT), VAT, C-reactive protein, and triglycerides compared to placebo. Reductions in cIMT — a validated surrogate marker of coronary atherosclerosis — are of particular interest to cardiovascular researchers, though the relative contributions of IGF-1 elevation, VAT reduction, and anti-inflammatory effects to this outcome continue to be investigated.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eCognitive \u0026amp; Neuroendocrine Research\u003c\/strong\u003e An emerging and scientifically compelling area of tesamorelin research concerns cognitive function and neuroendocrine biology. Given the well-established role of the GH\/IGF-1 axis in hippocampal neurogenesis, synaptic plasticity, and neuroprotection — and the progressive decline of GH secretion with age — tesamorelin has been investigated as a research tool for examining GH-mediated cognitive effects. Studies have explored tesamorelin's influence on verbal memory, executive function, and brain amyloid-beta metabolism in older adults, with findings suggesting a potential role for the GH\/IGF-1 axis in age-related cognitive trajectories that merits continued investigation.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eMetabolic Syndrome \u0026amp; Insulin Resistance Research\u003c\/strong\u003e Beyond the HIV-lipodystrophy indication, researchers have studied tesamorelin in broader models of visceral obesity and metabolic syndrome. Tesamorelin's stimulation of pulsatile GH release is thought to preferentially target visceral adipose tissue, suppress hepatic lipogenesis, and improve body-composition biomarkers. Its selectivity for visceral over subcutaneous fat — a pattern consistent with the physiological role of pulsatile GH in fat distribution — makes tesamorelin a valuable tool for researchers seeking to dissect the specific metabolic consequences of visceral adiposity and GH axis dysregulation.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cstrong\u003eAgeing \u0026amp; Somatopause Research\u003c\/strong\u003e The progressive decline in GH secretion with age — somatopause — is associated with increased visceral adiposity, reduced lean mass, impaired bone density, and deteriorating metabolic parameters. Tesamorelin's capacity to restore more youthful pulsatile GH dynamics without bypassing natural feedback mechanisms makes it an important research tool for studying somatopause-related metabolic changes and the role of the GH axis in healthy ageing trajectories. Unlike exogenous rhGH, which replaces GH directly and suppresses endogenous secretion, tesamorelin stimulates the pituitary — preserving the regulatory architecture while augmenting output.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eTesamorelin vs. Exogenous rhGH: A Key Research Distinction\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eA critical consideration for researchers choosing between tesamorelin and recombinant human growth hormone (rhGH) is the fundamentally different hormonal environment each creates. Direct rhGH administration delivers continuous, non-pulsatile GH exposure that can suppress endogenous GH secretion via negative feedback and frequently drives IGF-1 to supraphysiological levels — increasing the risk of insulin resistance and other GH excess effects. Tesamorelin, by contrast, stimulates the pituitary to release GH in the natural pulsatile pattern, maintains hypothalamic-pituitary feedback integrity, and produces more physiological IGF-1 elevation. This distinction is experimentally important: researchers studying the consequences of physiological versus supraphysiological GH axis activity, or seeking to model GH restoration without disrupting endocrine homeostasis, will find tesamorelin and rhGH produce meaningfully different experimental conditions that must be accounted for in protocol design.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eBoth tesamorelin and rhGH are available in our catalogue, allowing researchers to select the most appropriate tool for their specific experimental model.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eProduct Specifications\u003c\/h3\u003e\n\u003cdiv class=\"overflow-x-auto w-full px-2 mb-6\"\u003e\n\u003ctable class=\"min-w-full border-collapse text-sm leading-[1.7] whitespace-normal\"\u003e\n\u003cthead class=\"text-left\"\u003e\n\u003ctr\u003e\n\u003cth scope=\"col\" class=\"text-text-100 border-b-0.5 border-border-300\/60 py-2 pr-4 align-top font-bold\"\u003eSpecification\u003c\/th\u003e\n\u003cth scope=\"col\" class=\"text-text-100 border-b-0.5 border-border-300\/60 py-2 pr-4 align-top font-bold\"\u003eDetail\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003ePeptide\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eTesamorelin (TH9507)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eClassification\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eStabilised GHRH analogue — 44-amino acid polypeptide\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eN-terminal Modification\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eTrans-3-hexenoic acid (DPP-4 protection)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eMolecular Formula\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eC₂₂₁H₃₆₆N₇₂O₆₇S\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eMolecular Weight\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e5135.77 g\/mol\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003ePurity\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e\u0026gt;99% (HPLC \u0026amp; MS verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eForm\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eLyophilised powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eVial Sizes\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e5mg, 10mg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eAppearance\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eWhite to off-white powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eSolubility\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eSoluble in sterile water or bacteriostatic water\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eStorage\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e2–8°C (short-term); –20°C (long-term, lyophilised)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eShelf Life\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e24 months lyophilised; use reconstituted solution within 28 days (2–8°C)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003eCAS Number\u003c\/td\u003e\n\u003ctd class=\"border-b-0.5 border-border-300\/30 py-2 pr-4 align-top\"\u003e218949-48-5\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eQuality \u0026amp; Purity Assurance\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eEvery batch of our tesamorelin undergoes a comprehensive multi-stage quality control process before release. Our assurance pipeline includes:\u003c\/p\u003e\n\u003cul class=\"[li_\u0026amp;]:mb-0 [li_\u0026amp;]:mt-1 [li_\u0026amp;]:gap-1 [\u0026amp;:not(:last-child)_ul]:pb-1 [\u0026amp;:not(:last-child)_ol]:pb-1 list-disc flex flex-col gap-1 pl-8 mb-3\"\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eHPLC Analysis\u003c\/strong\u003e — confirms peptide purity exceeding 99% and correct modification profile\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eMass Spectrometry (MS)\u003c\/strong\u003e — verifies molecular identity, N-terminal hexenoyl modification integrity, and full 44-residue sequence accuracy\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eSDS-PAGE\u003c\/strong\u003e — confirms correct molecular weight profile under denaturing conditions\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eEndotoxin Testing\u003c\/strong\u003e — ensures the product is free from bacterial endotoxins\u003c\/li\u003e\n\u003cli class=\"font-claude-response-body whitespace-normal break-words pl-2\"\u003e\n\u003cstrong\u003eCertificate of Analysis (CoA)\u003c\/strong\u003e — available for every batch upon request\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eFull batch traceability is maintained across synthesis, purification, and quality testing. The N-terminal modification is an analytically critical feature of tesamorelin that requires specific MS verification — our QC process explicitly confirms hexenoyl conjugation integrity to ensure research-grade reliability.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eHandling \u0026amp; Reconstitution (Research Use)\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eTesamorelin lyophilised powder should be reconstituted by gently adding sterile bacteriostatic water to the side of the vial — not directly onto the powder. Swirl gently until fully dissolved; do not vortex. Once reconstituted, aliquot immediately and store at 2–8°C for short-term use (within 28 days) or at –20°C in lyophilised form for long-term storage. Avoid repeated freeze-thaw cycles to preserve the integrity of the N-terminal modification and peptide structure.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eAs a larger modified peptide, tesamorelin shares some storage sensitivity characteristics with rhGH and should be handled with the same care given to other complex peptide research compounds. All handling should comply with standard laboratory safety protocols and applicable institutional or regulatory guidelines.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003eTesamorelin Within the Research Peptide Catalogue\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eTesamorelin occupies a distinctive position within our catalogue as the only GHRH-axis upstream secretagogue — acting at the level of the hypothalamic-pituitary interface to stimulate endogenous GH production, rather than delivering GH directly as rhGH does. This upstream mechanism complements rhGH by allowing researchers to study pituitary-mediated GH secretion and the effects of physiological GH pulsatility, in contrast to the non-pulsatile exogenous GH exposure that rhGH produces.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eWithin the broader metabolic research landscape of the catalogue, tesamorelin's GH\/IGF-1 axis activity is mechanistically distinct from — and complementary to — the systemic triple hormone receptor agonism of retatrutide, the mitochondrial AMPK signalling of MOTS-c, and the intracellular NAD+ axis of 5-Amino-1MQ. Researchers studying visceral adiposity, metabolic ageing, or body composition from multiple mechanistic angles will find tesamorelin provides a physiological hormonal signalling perspective that is not replicated by any other compound in the catalogue.\u003c\/p\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003eAll peptides in our catalogue are manufactured to the same \u0026gt;99% purity standard and are supported by batch-specific Certificates of Analysis.\u003c\/p\u003e\n\u003chr class=\"border-border-200 border-t-0.5 my-3 mx-1.5\"\u003e\n\u003ch3 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003eImportant Notice\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e\u003cstrong\u003eThis product is intended strictly for in vitro research and laboratory use only. While tesamorelin (Egrifta) holds FDA approval for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, this research-grade product is not supplied for therapeutic use and must not be administered to humans or animals outside of appropriately authorised and supervised clinical contexts. It is not a supplement or food product. By purchasing this product, the buyer confirms they are a qualified researcher and will use the compound solely for lawful scientific research purposes.\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e","brand":"NEXYRALAB","offers":[{"title":"5mg","offer_id":59643106165070,"sku":null,"price":31.99,"currency_code":"GBP","in_stock":true},{"title":"10mg","offer_id":59643106197838,"sku":null,"price":58.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1035\/3351\/0990\/files\/hf_20260512_165945_694518ab-1023-49d6-a4fb-f65050e23721.png?v=1779451053","url":"https:\/\/nexyralab.com\/products\/tesamorelin-th9507","provider":"Nexyralab.com","version":"1.0","type":"link"}